31 May 2024
Abingdon Health Plc
("AH", the "Company" or the "Group")
Total Voting Rights - 31 May 2024
For the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), the Company's issued share capital as at 31 May 2024 consisted of 126,716,822 ordinary shares of 0.025 pence each in the Company ("Ordinary Shares"), and 182,316,812 Deferred Shares. The Deferred Shares do not confer any voting rights. The Company does not hold any shares in Treasury. Therefore, the total number of voting rights in the Company was 126,716,822.
The above figure of 126,716,822 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the DTRs.
For further information, please contact:
| Abingdon Health Plc Chris Yates, Chief Executive Officer Chris Hand, Non-Executive Chairman | www.abingdonhealth.com/investors |
| WH Ireland Limited (Sole Broker and Nominated Advisor) Chris Fielding / Isaac Hooper (Corporate Finance) Fred Marshall (Corporate Broking) | Tel: +44 (0)20 7220 1666
|
The person responsible for arranging the release of this announcement on behalf of the Company is Chris Yates, Chief Executive Officer of the Company.
About Abingdon Health plc
Abingdon Health is a leading lateral flow contract development and manufacturing organisation ("CDMO") offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from "idea to commercial success".
The Company's CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations; and produces lateral flow tests in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making and targeted intervention; and can support better outcomes.
Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test e-commerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland, such as pharmacy chains.
Founded in 2008, Abingdon Health is headquartered in York, England.
For more information visit: www.abingdonhealth.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
